Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Capital Employed (2021 - 2025)

Barinthus Biotherapeutics' Return on Capital Employed history spans 5 years, with the latest figure at 0.75% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 33.0% year-over-year to 0.75%; the TTM value through Dec 2025 reached 0.75%, down 33.0%, while the annual FY2025 figure was 0.59%, 20.0% down from the prior year.
  • Return on Capital Employed reached 0.75% in Q4 2025 per BRNS's latest filing, up from 0.76% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.02% in Q3 2022 to a low of 0.76% in Q3 2025.
  • Average Return on Capital Employed over 5 years is 0.32%, with a median of 0.32% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: rose 17bps in 2022, then tumbled -42bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 0.18% in 2021, then soared by 91bps to 0.02% in 2022, then plummeted by -2529bps to 0.4% in 2023, then decreased by -7bps to 0.43% in 2024, then plummeted by -76bps to 0.75% in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Return on Capital Employed are 0.75% (Q4 2025), 0.76% (Q3 2025), and 0.62% (Q2 2025).